Better Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 14, 2022

Rhea-AI Summary

Better Therapeutics, Inc. (NASDAQ: BTTX) will announce its third quarter 2022 financial results on November 14, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. ET to provide a business update. Better Therapeutics specializes in prescription digital therapeutics using cognitive behavioral therapy to combat cardiometabolic diseases. Their innovative approach aims to alter neural pathways, enabling lasting behavioral changes. If approved, their mobile applications could be prescribed and reimbursed similar to traditional medications.

Positive

• Upcoming conference call on November 14 for Q3 2022 financial results.
• Company focuses on developing innovative digital therapeutics for cardiometabolic diseases.

Negative

• None.

SAN FRANCISCO--(BUSINESS WIRE)-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced it will release its third quarter 2022 financial results after the market closes on Monday, November 14, 2022. Management will host a conference call and webcast to provide a business update at 4:30 p.m. ET / 1:30 p.m. PT on Monday, November 14, 2022.

To access the conference call, please register at: https://register.vevent.com/register/BI2c729f96a5894042b72aa89ac43ae0c8. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. The live webcast may be accessed by visiting the event link at: https://edge.media-server.com/mmc/p/uritguso. Following the webcast, a replay of the webcast may be accessed from the Presentations & Events page in the Investors section of the Better Therapeutics corporate website at: investors.bettertx.com.

About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The CBT delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics’ clinically validated mobile applications, if authorized for marketing, are intended to be prescribed by physicians and reimbursed like traditional medicines.

For more information visit: bettertx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005117/en/

Investor Relations:

Mark Heinen

IR@bettertx.com

Media:

Ryan McKenna at Real Chemistry

rmckenna@realchemistry.com

Source: Better Therapeutics, Inc.

FAQ

When will Better Therapeutics release its Q3 2022 financial results?

Better Therapeutics will release its Q3 2022 financial results on November 14, 2022, after the market closes.

What is the purpose of the Better Therapeutics conference call on November 14?

The conference call on November 14 will provide a business update following the release of Q3 2022 financial results.

What is Better Therapeutics' main focus?

Better Therapeutics focuses on developing prescription digital therapeutics that utilize cognitive behavioral therapy to address cardiometabolic diseases.